Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vapotherm

Explore full profile

Develops and manufactures innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders

Exeter, United KingdomFounded 1999Biotech & Life Sciences
Valuation $133M Market cap · 2024
Revenue $69M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Vapotherm

Vapotherm is a medical technology company specializing in advanced respiratory care solutions. The company provides high velocity therapy, a form of non-invasive ventilation (NIV) that offers ventilatory support without the need for a mask. This technology is particularly beneficial for patients who are mask intolerant, providing a more comfortable and effective alternative to traditional methods. Vapotherm's products are used across various patient populations, from adults with chronic obstructive pulmonary disease (COPD) in emergency departments to delicate infants in neonatal intensive care units (NICU). The company serves a wide range of healthcare providers, including hospitals and emergency care facilities, and has treated over 3.3 million patients globally. Vapotherm operates in the medical device market, focusing on respiratory care. Its business model revolves around the sale of its high velocity therapy systems and related consumables, generating revenue through both initial equipment sales and ongoing supply of disposable components. The company is backed by extensive clinical research and is trusted by over 2,200 hospitals worldwide.

Source: Dealroom company data

At a glance

Founded
1999
Headquarters
Exeter, United Kingdom
Listing
IPO 2018
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning Vapotherm.

See all news

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Gilde Healthcare

Series B and later11 investors entered at this stage

  • GE Asset Management
  • Kaiser Permanente Ventures
  • QuestMark Partners
  • Integral Capital Partners
  • SightLine Partners
  • Adage Capital
  • Crestline Investors
  • Arnerich Massena
  • Perceptive Advisors
  • Redmile Group
  • CIBC Innovation Banking
Team profiled 22 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
12 countries with
team presence
🇺🇸 United States72.8%
🇲🇽 Mexico12.8%
🇸🇬 Singapore3.9%
🇬🇧 United Kingdom3.3%
🇧🇷 Brazil2.2%
Top 5 of 12 shown
Web traffic by country
8.2K monthly visits
across markets
🇺🇸 United States62.2%
🇧🇷 Brazil25.6%
🇮🇳 India12.2%
Top 3 markets shown

Patents

Estimated portfolio value
$41M

39 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vapotherm on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vapotherm on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.